This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged ...
For her entire life, college student Olivia Cook had only a small degree of central vision. It was as if she was watching the world through a straw hole, and in dimly lit places, she could not make ...
Experimental gene therapy studied in both China and the United States has allowed several children born with inherited deafness to hear. On Tuesday, the Children's Hospital of Philadelphia announced ...
A new gene-editing therapy called Casgevy, which is designed to help treat patients suffering from sickle cell disease, has been endorsed by the National Catholic Bioethics Center and its president, ...
Researchers at University of California San Diego School of Medicine have developed a gene therapy for Alzheimer’s disease that could help protect the brain from damage and preserve cognitive function ...
Moorfields Eye Hospital in London made international headlines last week. Doctors announced they had saved the sight of four young children suffering from a rare genetic condition that rapidly causes ...
New gene therapy trial shows restored hearing and speech in children born deaf, treated in both ears
A new clinical trial of five children with inherited deafness found administering gene therapy in both ears led to restored hearing and speech, and additional gains including sound source localization ...
CGTs present significant challenges across diagnosis, treatment, and post-treatment stages, requiring coordinated stakeholder efforts to streamline processes and reduce barriers. Early diagnosis and ...
Even hearing the phrase “Huntington’s disease” will make a room suddenly somber. So the joy that accompanied a recent announcement of results of an experimental gene therapy for the deadly diseases ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is ...
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of Beqvez ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback